Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

FAM-TRASTUZUMAB DERUXTECAN-NXKI for Breast cancer metastatic: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 1,774 adverse event reports in the FDA FAERS database where FAM-TRASTUZUMAB DERUXTECAN-NXKI was used for Breast cancer metastatic.

Most Reported Side Effects for FAM-TRASTUZUMAB DERUXTECAN-NXKI

Side Effect Reports % Deaths Hosp.
Nausea 1,037 13.8% 129 270
Interstitial lung disease 880 11.7% 280 355
Disease progression 794 10.6% 432 263
Death 717 9.5% 717 73
Fatigue 652 8.7% 32 86
Off label use 651 8.7% 123 112
Vomiting 464 6.2% 71 175
Diarrhoea 463 6.2% 65 194
Pneumonitis 337 4.5% 100 131
No adverse event 315 4.2% 0 0
Decreased appetite 301 4.0% 71 133
Alopecia 282 3.8% 19 39
Asthenia 250 3.3% 22 76
Dyspnoea 235 3.1% 63 101
Intentional product use issue 234 3.1% 21 62

Other Indications for FAM-TRASTUZUMAB DERUXTECAN-NXKI

Her2 positive breast cancer (1,578) Product used for unknown indication (1,349) Breast cancer (1,059) Her2 low breast cancer (643) Her2 positive gastric cancer (353) Her2 negative breast cancer (220) Gastric cancer (179) Breast cancer female (157) Her2 mutant non-small cell lung cancer (101) Non-small cell lung cancer (87)

Other Drugs Used for Breast cancer metastatic

PALBOCICLIB (18,160) RIBOCICLIB (9,771) LETROZOLE (6,856) TRASTUZUMAB (6,303) FULVESTRANT (4,570) PERTUZUMAB (3,784) CAPECITABINE (3,691) PACLITAXEL (3,241) DOCETAXEL (3,070) EVEROLIMUS (2,751)

Related Pages

FAM-TRASTUZUMAB DERUXTECAN-NXKI Full Profile All Breast cancer metastatic Drugs FAM-TRASTUZUMAB DERUXTECAN-NXKI Demographics FAM-TRASTUZUMAB DERUXTECAN-NXKI Timeline